European Medicines Agency jeopardizes investments in drug development - .PDF file.
The heart of a marketing authorisation application is the pre-clinical and clinical data that proves the drug’s safety and efficacy. This data is collected through substantial investments in time and money. The current and proposed policies of the European Medicines Agency threaten the confidentiality, and hence the business value, of these investments.
Click on the link above to download this Jones Day briefing.